Janus Henderson Group PLC Crinetics Pharmaceuticals, Inc. Transaction History
Janus Henderson Group PLC
- $188 Billion
- Q4 2024
A detailed history of Janus Henderson Group PLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,795,441 shares of CRNX stock, worth $91 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,795,441
Previous 2,429,450
15.06%
Holding current value
$91 Million
Previous $124 Million
15.18%
% of portfolio
0.08%
Previous 0.07%
Shares
18 transactions
Others Institutions Holding CRNX
# of Institutions
254Shares Held
89.2MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$296 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$226 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$203 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$200 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$176 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.75B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...